Vitamin K2 is a family of naturally occurring fat-soluble vitamins called menaquinones, found in fermented and animal-derived foods and, in certain forms, produced within the body; human research has primarily examined Bone Health, Cardiovascular Health, Nutrition and Deficiencies, and vitamin K-dependent protein function. (NIH ODS)
Vitamin K2 is not one chemical compound but a group of related forms, including MK-4, MK-7, MK-8, and MK-9, which differ in molecular structure, dietary sources, and behavior after absorption. (NIH ODS) MK-7 is prominent in modern randomized trials involving bone density, arterial stiffness, and vascular calcification, while MK-4 features in older osteoporosis research, often at substantially higher experimental doses. (Research) (Research) Human studies consistently investigate vitamin K-dependent biochemical markers, but results for bone density and vascular outcomes are mixed. (Review) The overall clinical evidence remains less conclusive than the biochemical evidence, particularly for fracture reduction and cardiovascular events. (Review)
Ingredient Identity
- Official name: Vitamin K2 (menaquinones).
- Classification: Fat-soluble vitamin family; naphthoquinone derivatives.
- Principal forms: Menaquinone-4 (MK-4), menaquinone-7 (MK-7), menaquinone-8 (MK-8), and menaquinone-9 (MK-9).
- Additional forms: MK-5, MK-6, MK-10, MK-11, MK-12, and MK-13.
- Synonyms: Vitamin K2; menaquinone; MK-n; menatetrenone (MK-4).
- CAS identification: Varies by specific menaquinone; Vitamin K2 is a family rather than one substance with one universally applicable CAS number.
- Endogenous status: MK-4 can be formed through conversion from vitamin K1; gut microorganisms also produce certain menaquinones.
- Exogenous status: Available through foods and manufactured ingredients.
These structural and biological distinctions are described in the NIH vitamin K reference. (NIH ODS)
Ingredient Snapshot
Classification: Fat-soluble vitamin family comprising menaquinones (MK-4, MK-7, MK-8, MK-9, and related forms). (NIH ODS)
Endogenous vs. Exogenous: Obtained through food; MK-4 can also be formed through conversion within the body. (NIH ODS)
Primary Human Research Domains: Bone Health, Cardiovascular Health, Kidney Health, Diabetes and Glycemic Control, and Nutrition and Deficiencies. (Review) (Research)
Common Study Formats: Randomized oral supplementation trials, observational dietary cohorts, and human pharmacokinetic investigations. (Research)
Pharmacokinetic Characterization: MK-7 demonstrates longer circulating persistence than MK-4 under directly compared study conditions. (Research)
Regulatory Context: Dietary nutrient and supplement ingredient in the U.S.; specific Vitamin K2 preparations are subject to EU authorization requirements. (NIH ODS) (EU Authority)
Evidence Maturity: Established nutritional functions, with mixed human evidence for bone-density and cardiovascular outcomes. (Review)
Introduction
Vitamin K2 belongs to the vitamin K family but differs from vitamin K1 in the length and structure of its molecular side chain. Vitamin K1 predominates in leafy vegetables, whereas menaquinones occur particularly in fermented and selected animal-derived foods. MK-7 is associated with natto, a fermented soybean food, and longer-chain menaquinones occur in various fermented cheeses; MK-4 can also be produced through conversion of vitamin K1 within the body. (NIH ODS)
Scientific interest in Vitamin K2 extends beyond its established vitamin K-dependent functions because human studies have examined bone-density preservation, arterial stiffness, vascular calcification, glucose regulation, and biochemical markers of vitamin K availability. MK-7 has attracted particular research attention because it remains detectable in circulation for longer than MK-4 under some directly compared experimental conditions. However, absorption characteristics and biomarker responses do not establish equivalent clinical benefits. (Research) (Research)
This article is informational only, describes Vitamin K2 as a biochemical substance studied in human research, and does not provide medical or dosing advice.
Quick Summary
- Vitamin K2 is a family of menaquinones, not a single interchangeable ingredient; MK-4, MK-7, MK-8, and MK-9 differ in their natural occurrence and physiological behavior. (NIH ODS)
- MK-7 has been studied in randomized trials lasting up to three years, particularly for Bone Health and Cardiovascular Health, with mixed results for bone density and vascular measures. (Research) (Research)
- MK-4 has a separate clinical research history, including 45 mg/day osteoporosis trials, substantially different from the microgram quantities used in many MK-7 trials. (Research)
- MK-7 can influence vitamin K-dependent protein activation, including osteocalcin-related biomarkers, but biomarker improvements do not consistently correspond to measurable bone-density changes. (Research)
- Cardiovascular intervention studies report variable results across arterial stiffness, coronary artery calcification, and aortic valve calcification. (Research) (Research)
- Dietary MK-7, MK-8, and MK-9 intake has been associated with coronary outcomes in observational cohorts, but these studies cannot establish causality. (Research)
- Vitamin K2 can interfere with vitamin K antagonist anticoagulants, and human experimental research has documented effects from relatively small MK-7 exposures. (Research)
Human Research Findings by Condition
Bone Health
Bone Health is one of the most extensively investigated areas of Vitamin K2 research, with randomized trials of both MK-7 and MK-4 in postmenopausal women and people with osteoporosis. Some studies report favorable bone-density changes or fewer fractures, whereas other well-controlled studies find no significant differences in bone density or bone microarchitecture. (Review) (Research)
Key human study — MK-7, Knapen et al., 2013
Dose studied: 180 µg/day MK-7
Population: 244 healthy postmenopausal women
Duration: 3 years
Researchers measured changes in bone mineral density and bone strength during prolonged MK-7 supplementation. The MK-7 group experienced less age-related bone-density decline at selected skeletal sites, including the lumbar spine and femoral neck, although the findings were not uniform across all measured regions.
Result: Randomized human trial reported a statistically significant improvement in selected bone outcomes.
Evidence strength: Moderate
Study source: (Research)
Additional human study — MK-7, Rønn et al., 2021
Dose studied: 375 µg/day MK-7, alongside calcium and vitamin D
Population: 142 postmenopausal women with osteopenia completing follow-up
Duration: 3 years
This trial evaluated bone density and structural properties using imaging methods capable of examining bone microarchitecture. Despite changes in vitamin K-dependent biochemical measures, MK-7 produced no significant improvement in the primary bone-density or microarchitecture outcomes compared with placebo.
Result: Human clinical study reported no clear effect.
Evidence strength: Moderate
Study source: (Research)
Additional human study — MK-4, Shiraki et al., 2000
Dose studied: 45 mg/day MK-4
Population: 241 patients with osteoporosis
Duration: 24 months
This randomized, open-label study examined pharmacological-dose MK-4 and reported favorable fracture-related findings compared with an untreated control group. Interpretation is limited by the historical trial design, lack of blinding, and differences from contemporary placebo-controlled osteoporosis research.
Result: Randomized human trial reported a statistically significant improvement in fracture-related outcomes.
Evidence strength: Limited
Study source: (Research)
Cardiovascular Health
Human research has examined arterial stiffness, coronary artery calcium scores, aortic valve calcification, and dietary associations with coronary heart disease. Results vary by outcome, baseline disease status, Vitamin K2 subtype, and whether vitamin D was administered simultaneously; direct evidence for fewer heart attacks, strokes, or cardiovascular deaths remains insufficient. (Research) (Review)
Key human study — MK-7, Knapen et al., 2015
Dose studied: 180 µg/day MK-7
Population: 244 postmenopausal women
Duration: 3 years
Researchers measured changes in arterial stiffness, a characteristic describing how readily arteries expand with each heartbeat. Selected stiffness measures improved in the MK-7 group, with more pronounced findings among participants with elevated stiffness at baseline.
Result: Randomized human trial reported a statistically significant improvement in selected vascular measures.
Evidence strength: Moderate
Study source: (Research)
Additional human study — DANCODE, 2026
Dose studied: 720 µg/day vitamin K2 plus 25 µg/day vitamin D3
Population: 400 randomized participants with severe coronary artery calcification
Duration: 24 months
This study assessed changes in calcified plaque measured by coronary computed tomography. The combination intervention was associated with slower calcium-score progression, but the design does not distinguish the independent contribution of K2 from vitamin D3, and a change in imaging does not by itself establish fewer clinical cardiovascular events.
Result: Randomized human trial reported a statistically significant improvement in an imaging outcome.
Evidence strength: Limited
Study source: (Research)
Additional human study — dietary menaquinones, Gast et al., 2009
Exposure studied: Habitual dietary K2 intake, including MK-7, MK-8, and MK-9
Population: 16,057 women
Duration: Mean follow-up of 8.1 years
Researchers estimated individual dietary menaquinone intake and followed participants for coronary heart disease events. Higher intake of certain menaquinones was associated with lower coronary heart disease incidence, although diet-related confounding and the observational design prevent a causal interpretation.
Result: Observational human studies reported an association.
Evidence strength: Observational
Study source: (Research)
Kidney Health
Kidney Health studies have concentrated on people receiving hemodialysis, a population in whom vascular calcification and altered vitamin K-dependent biomarkers are frequent research concerns. Randomized supplementation trials have generally found improvements in biochemical markers without consistent improvement in vascular calcification measurements. (Research)
Key human study — Trevasc-HDK, 2023
Dose studied: 360 µg MK-7 three times weekly
Population: 178 randomized hemodialysis patients
Duration: 18 months
Researchers investigated whether MK-7 altered the progression of coronary artery calcification. No statistically significant improvement in the principal coronary calcification outcome was demonstrated.
Result: Human clinical study reported no clear effect.
Evidence strength: Moderate
Study source: (Research)
Diabetes and Glycemic Control
Metabolic research has evaluated whether MK-7 influences fasting glucose, long-term glucose markers, insulin sensitivity, and adiponectin, a hormone involved in metabolic regulation. Findings are preliminary and inconsistent between study populations and endpoints. (Research) (Research)
Key human study — MK-7 and type 2 diabetes
Dose studied: 360 µg/day MK-7
Population: 68 adults with type 2 diabetes
Duration: 12 weeks
This randomized trial measured fasting glucose and glycated hemoglobin (HbA1c), which reflects average blood glucose over preceding weeks. It reported improvements relative to placebo, but its modest size and short duration limit interpretation of longer-term clinical significance.
Result: Randomized human trial reported a statistically significant improvement.
Evidence strength: Limited
Study source: (Research)
Additional human study — Rønn et al., 2021
Dose studied: 375 µg/day MK-7
Population: 148 postmenopausal women
Duration: 12 months
Investigators measured insulin sensitivity and circulating adiponectin. Although adiponectin increased, measured insulin sensitivity did not improve, illustrating why favorable biomarker findings do not necessarily establish improved glucose regulation.
Result: Human clinical study reported no clear effect on insulin sensitivity.
Evidence strength: Moderate
Study source: (Research)
Nutrition and Deficiencies
This research area includes the effect of menaquinones on vitamin K status and the activation of proteins that require vitamin K to function. Controlled studies consistently use markers such as undercarboxylated osteocalcin, but these biochemical measures are not substitutes for fracture rates or other clinical endpoints. (Research) (NIH ODS)
Key human study — MK-7 in children
Dose studied: 45 µg/day MK-7
Population: 55 healthy prepubertal children
Duration: 8 weeks
Researchers measured osteocalcin carboxylation, a biochemical process requiring vitamin K. Supplementation improved the relevant laboratory marker, but the study did not establish improvements in fracture outcomes or future skeletal health.
Result: Human studies observed short-term physiological effects.
Evidence strength: Limited
Study source: (Research)
Additional human study — Emaus et al., 2010
Dose studied: 360 µg/day MK-7
Population: 334 early postmenopausal women
Duration: 12 months
Researchers assessed osteocalcin activation alongside bone-density outcomes. MK-7 improved the biochemical measure without significantly changing the rate of bone-density loss, demonstrating a separation between nutritional biomarker response and clinical bone measurements.
Result: Human clinical studies reported mixed findings.
Evidence strength: Moderate
Study source: (Research)
Obesity and Weight Regulation
Research on body composition has been secondary to bone and cardiovascular outcomes rather than a major independent clinical research program. A long-term MK-7 analysis did not identify a consistent overall improvement in body composition, and subgroup findings should be considered exploratory. (Research)
Key human study — MK-7 and body composition
Dose studied: 180 µg/day MK-7
Population: 214 postmenopausal women
Duration: 3 years
Researchers analyzed body-composition changes during a prolonged MK-7 intervention. No clear overall body-composition effect was identified, although some subgroup observations were reported.
Result: Human clinical study reported no clear effect.
Evidence strength: Limited
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Human Vitamin K2 research includes estimated dietary intake, low-microgram MK-7 supplementation, higher-microgram intervention trials, single-dose absorption studies, and milligram-range MK-4 studies. These represent different experimental questions and cannot be treated as one continuous dose-response relationship. MK-7 research has commonly used microgram quantities, while selected MK-4 osteoporosis studies have used 45 mg/day, equivalent to 45,000 µg/day. (Research) (Research)
Dietary exposure
29.1 µg/day — mean dietary menaquinone intake in a cohort:
In the Prospect-EPIC cohort, researchers estimated habitual menaquinone intake through dietary questionnaires rather than assigning a supplement. The reported average K2 intake was approximately 29.1 µg/day, comprising different menaquinone forms. Participants were followed for an average of 8.1 years, and higher dietary menaquinone intake was associated with lower coronary heart disease incidence. This finding describes a population-level association rather than an intervention effect. The study cannot identify the effects of isolated MK-7 separately from other dietary factors. (Research)
Result: Observational association
Evidence strength: Observational
Notes / limitations: Dietary menaquinones were evaluated as part of habitual food consumption, not as individually randomized supplements.
Supplemental exposures
10–45 µg/day MK-7:
This low-dose range was studied in healthy volunteers whose anticoagulation was controlled with acenocoumarol. Researchers investigated whether small MK-7 exposures altered the anticoagulant response. Changes occurred even at relatively low intakes in some participants, illustrating that a substance can influence vitamin K-dependent physiology without producing a visible symptom or clinical benefit. The study’s relevance concerns drug interaction and vitamin K activity rather than Bone Health or Cardiovascular Health outcomes. Its conclusions are specific to vitamin K antagonist anticoagulation. (Research)
Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: Findings concern anticoagulated participants and cannot be interpreted as an efficacy dose-response study.
45 µg/day MK-7:
A pediatric randomized study evaluated 45 µg/day of MK-7 in 55 children over eight weeks. Its primary research interest was the activation of osteocalcin, a protein involved in bone physiology. Investigators reported a favorable change in the vitamin K-dependent biochemical marker. Bone-density and fracture outcomes were not established in this short study. The finding therefore provides evidence of nutritional biochemical activity rather than proof of a long-term skeletal benefit. (Research)
Result: Statistically significant improvement in a biochemical marker
Evidence strength: Limited
Notes / limitations: Short-term biomarker findings cannot establish long-term outcomes in growing children.
45–180 µg/day MK-7 — formulation comparison:
Human studies compared synthetic and fermentation-derived MK-7 preparations under controlled conditions. Researchers assessed blood concentrations and vitamin K-dependent biochemical responses, including a functional study lasting approximately six weeks. The tested preparations showed broadly comparable bioavailability, while biomarker changes varied with exposure. These findings provide formulation-specific information rather than evidence that all products or manufacturing methods produce identical absorption. The study did not establish superior clinical bone or cardiovascular outcomes for either tested preparation. (Research)
Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Notes / limitations: Comparability applies to the preparations evaluated in the original research.
60 µg/day MK-4 versus MK-7 — direct pharmacokinetic comparison:
Healthy Japanese women participated in a controlled study comparing the circulating behavior of MK-4 and MK-7. In the repeated-exposure component, researchers examined the forms at 60 µg/day, while a separate experiment evaluated larger single exposures. Under the measured conditions, MK-7 produced more persistent detectable blood concentrations than MK-4. The investigation therefore helps explain why trials using the same quantity of different menaquinones should not automatically be considered pharmacokinetically equivalent. It did not compare long-term fracture or cardiovascular outcomes. (Research)
Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Notes / limitations: Blood concentration differences do not establish superior clinical performance of one form.
180 µg/day MK-7:
One long-term randomized program evaluated 180 µg/day MK-7 in 244 postmenopausal women over three years. Researchers investigated both skeletal and vascular outcomes in related publications. Bone analyses found less age-related decline in selected skeletal measurements, while a vascular analysis reported favorable arterial-stiffness changes, particularly among participants with greater stiffness initially. The duration makes these studies informative for understanding prolonged exposure, although their endpoints were mainly physiological or imaging-based rather than fractures or clinical cardiovascular events. These related publications represent the same study population and should not be interpreted as independent replication. (Research) (Research)
Result: Statistically significant improvement in selected measured outcomes
Evidence strength: Moderate
Notes / limitations: Findings require comparison with other trials that reported neutral results.
360 µg/day MK-7:
Several randomized investigations evaluated this exposure in differing populations, including early postmenopausal women and adults with type 2 diabetes. A 12-month bone study reported improved vitamin K-dependent osteocalcin activation without a significant difference in bone-density loss, whereas a smaller 12-week metabolic study reported improved glucose-related measurements. These outcomes represent different physiological systems and should not be combined into one generalized benefit claim. Their differing durations also limit direct comparisons of clinical significance. (Research) (Research)
Result: Mixed findings
Evidence strength: Limited
Notes / limitations: Similar nominal doses cannot eliminate differences in population, study outcome, or clinical context.
360 µg MK-7 three times weekly:
The Trevasc-HDK randomized study examined MK-7 administered three times per week to participants undergoing hemodialysis. Researchers evaluated coronary artery calcification over 18 months rather than merely measuring short-term vitamin K status. The study did not demonstrate a significant improvement in the principal coronary calcification outcome. This finding provides evidence about a specific kidney-disease population and intermittent exposure schedule. It should not be treated as equivalent to a daily 360 µg supplementation protocol. (Research)
Result: No clear effect
Evidence strength: Moderate
Notes / limitations: The intermittent schedule and dialysis population limit generalization.
375 µg/day MK-7:
A randomized clinical program examined MK-7 alongside calcium and vitamin D in postmenopausal women with osteopenia. Researchers followed skeletal measurements, including density and microarchitecture, through three years. Although some earlier measurements and biochemical responses had attracted interest, the three-year report found no significant difference in the key bone outcomes between MK-7 and placebo. This result is particularly relevant because it provides a long-duration contrast with favorable findings reported in another MK-7 trial. It does not mean that the substance was biologically inactive. (Research)
Result: No clear effect
Evidence strength: Moderate
Notes / limitations: Background calcium and vitamin D intake were part of the study context.
420 µg single exposure — MK-4 versus MK-7:
A controlled human absorption study compared single exposures of MK-4 and MK-7 at 420 µg. Investigators collected serial blood samples and examined the time course of circulating menaquinones. MK-7 reached a measurable peak and remained detectable longer, while MK-4 was not detected to the same extent under the study conditions. The results characterize absorption and circulation rather than sustained clinical benefit. They also demonstrate that a one-time laboratory exposure should be distinguished from months or years of daily supplementation. (Research)
Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Notes / limitations: A single-dose comparison cannot establish the optimal form or exposure for clinical outcomes.
720 µg/day Vitamin K2 plus vitamin D3:
Two-year cardiovascular research has examined this relatively high MK-7 exposure combined with vitamin D3. In a randomized study of men with aortic valve calcification, the combination did not significantly slow progression of the principal valve-calcification outcome. A separate coronary-calcification trial reported a more favorable imaging result in a different cardiovascular population. Together, the findings illustrate outcome-specific heterogeneity rather than a uniform response across blood vessels and heart valves. Because both interventions included vitamin D3, the independent contribution of MK-7 cannot be determined from these comparisons alone. (Research) (Research)
Result: Mixed findings
Evidence strength: Limited
Notes / limitations: Combined interventions and differing calcification endpoints prevent attribution solely to MK-7.
1 mg MK-7 — single-dose pharmacokinetic exposure:
A human pharmacokinetic investigation administered a single 1 mg MK-7 exposure to healthy male volunteers. Researchers measured circulating MK-7 over time to characterize absorption, peak concentration, and elimination. Peak concentrations occurred around six hours after administration in the reported study conditions, with measurable persistence thereafter. This provides useful information about the behavior of MK-7 after a comparatively large single exposure. It does not establish an appropriate chronic intake or a clinical dose-response relationship. (Research)
Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Notes / limitations: Single-dose pharmacokinetics cannot be directly extrapolated to chronic clinical outcomes.
45 mg/day MK-4 (45,000 µg/day):
Selected Japanese osteoporosis trials examined MK-4 in milligram rather than microgram quantities. One historical randomized study of 241 participants reported fewer clinical fractures over two years, while a more recent controlled study involving 105 women did not find significant additional bone-density improvements when MK-4 was added to existing treatments. These differing findings reflect changes in study design, concurrent therapies, populations, and measured endpoints. The research should be interpreted as specific to MK-4 and not transferred automatically to ordinary microgram-range MK-7 exposures. (Research) (Research)
Result: Mixed findings
Evidence strength: Limited
Notes / limitations: The evidence spans substantially different trial designs and cannot establish interchangeability between MK-4 and MK-7.
Key Takeaways from Human Research
- Bone Health: MK-7 has produced favorable bone-density findings in some long-term trials, but other three-year randomized research found no measurable benefit. (Research) (Research)
- Cardiovascular Health: Some trials report changes in arterial stiffness or calcium-score progression, whereas others report neutral calcification outcomes; reductions in cardiovascular events remain unestablished. (Research) (Review)
- MK-4 versus MK-7: Their absorption profiles and studied exposure ranges differ materially, making subtype-specific interpretation important. (Research) (Research)
- Nutrition and Deficiencies: Changes in vitamin K-dependent protein activation are documented in human trials, but biochemical changes should not be interpreted as proof of clinical benefit. (Research)
- MK-8 and MK-9: Much of the evidence concerns associations between habitual dietary intake and health outcomes rather than isolated intervention trials. (Research)
- Safety: Vitamin K antagonists are a documented interaction category, including in studies of low MK-7 exposures. (Research)
Origin & Natural Occurrence
Menaquinones are found in foods through several different biological processes. Microorganisms involved in fermentation produce long-chain menaquinones, while MK-4 can be formed in the body by conversion from vitamin K1. The intestinal microbiota also synthesize menaquinones, although their contribution to human nutritional availability remains incompletely established. (NIH ODS)
MK-4 is associated with animal-derived foods and endogenous conversion. MK-7 is strongly associated with natto, whereas longer-chain forms such as MK-8 and MK-9 occur in certain fermented dairy products. The amount and distribution of menaquinones vary by food and fermentation conditions, so a food described as containing K2 does not necessarily contain the same subtype as another K2-containing food. (NIH ODS)
Manufactured Vitamin K2 ingredients can be produced using microbial fermentation or synthetic processes. Human formulation research has compared specific synthetic and fermentation-derived MK-7 preparations and reported broadly comparable biological availability under the conditions examined. Such findings do not establish identical properties for every commercial formulation. (Research)
How It Behaves in the Body
Vitamin K2 supports the activation of particular proteins that participate in normal bodily processes. Some of these proteins are involved in blood coagulation, others in bone biology, and others in regulating mineral deposition in soft tissues. Without sufficient vitamin K activity, these proteins may remain incompletely activated, even when their total concentration is measurable. (NIH ODS)
The central biochemical process is gamma-carboxylation, a reaction that modifies selected proteins so that they can interact appropriately with calcium. Osteocalcin is one vitamin K-dependent protein examined in Bone Health studies, while matrix Gla protein is important in research concerning vascular calcification. MK-7 interventions have repeatedly been studied through changes in the inactive or undercarboxylated forms of these proteins. (Research) (Review)
Vitamin K is recycled through an enzymatic system often called the vitamin K cycle, enabling it to participate repeatedly in the activation of vitamin K-dependent proteins. Vitamin K antagonist anticoagulants interfere with this process, explaining why changes in vitamin K exposure can influence their effects. (NIH ODS)
After ingestion, Vitamin K2 forms are absorbed through pathways associated with dietary fats and transported in circulating lipoproteins. Their side-chain differences affect distribution and persistence in the bloodstream, and human studies have demonstrated different concentration-time profiles for MK-4 and MK-7. (Research)
The biochemical requirement for vitamin K is well established. Whether additional MK-7 or MK-4 exposure consistently changes long-term bone or cardiovascular outcomes in adequately nourished populations is a separate question, and the human intervention evidence remains mixed. (Review) (Review)
Absorption & Delivery Formats
Oral immediate-release
Most human Vitamin K2 research has investigated oral administration, often as capsules or within food-based preparations. Absorption is influenced by fat-associated digestive processes, and circulating MK-7 can be measured after oral exposure in controlled studies. (Research)
Oral extended-release
The available cited human research does not adequately characterize extended-release MK-7 or MK-4 systems against conventional oral formulations for clinically meaningful outcomes. No comparative claim about superior sustained delivery can be established from this evidence set.
Sublingual
The cited clinical research does not provide sufficient controlled human evidence to characterize sublingual Vitamin K2 absorption, bioavailability, or clinical outcomes relative to oral administration.
Transdermal
Human evidence is insufficient in the cited research to evaluate transdermal delivery, systemic exposure, or clinical effectiveness for Vitamin K2.
Injectable / IV
The evidence reviewed for this article does not establish an injectable MK-7 or MK-4 research framework comparable with the oral trials discussed above. The use of other vitamin K compounds in medical settings should not be treated as evidence about injectable MK-7.
Quick Facts at a Glance
Onset (reported)
A measurable biochemical or blood-concentration response is not necessarily a clinically meaningful effect. Controlled pharmacokinetic studies have detected circulating MK-7 within hours of oral exposure, while changes in protein activation have been examined over days or weeks. (Research) (Research)
Time to peak (Tmax)
A direct MK-4 versus MK-7 comparison reported a plasma concentration peak for MK-7 at approximately six hours after a single oral exposure. A separate MK-7 pharmacokinetic investigation also reported peak concentrations around this time, although individual values can vary with formulation and experimental conditions. (Research) (Research)
Half-life (t½)
MK-7 demonstrates prolonged blood persistence compared with MK-4 in directly compared human experimental conditions. Its elimination profile is not interchangeable with a single universal half-life because measured values depend on the experimental population, dose, and analysis method. (Research) (Research)
Typical duration
Vitamin K-dependent biomarker studies have examined effects over weeks, whereas major bone and vascular intervention trials have extended to two or three years. These are observation periods selected by investigators, not evidence that clinical effects necessarily begin or end at corresponding time points. (Research) (Research)
Absorption routes studied
Oral absorption is the best-characterized route within the human evidence reviewed. Experimental studies have investigated purified or manufactured MK-7 as well as food-associated delivery, allowing researchers to compare blood concentrations and selected biochemical responses. (Research) (Research)
Formulation differences
MK-4 and MK-7 have different circulation profiles, while specific fermentation-derived and synthetic MK-7 preparations have shown broadly comparable measured availability in controlled research. Neither observation establishes that every formulation delivers equivalent clinical effects. (Research) (Research)
Variability drivers
Form, food matrix, concurrent intake conditions, baseline vitamin K status, and participant characteristics may influence exposure or measured response. Controlled investigations and NIH nutritional guidance help explain why nominal dose alone is insufficient to characterize Vitamin K2 activity. (NIH ODS) (Research)
Tolerance / adaptation
The available human studies do not establish a well-defined tolerance syndrome in which repeated MK-7 exposure produces progressively reduced clinical responsiveness. Long-term trials have instead emphasized biochemical, skeletal, and vascular outcomes, so absence of a documented tolerance pattern is not equivalent to definitive evidence that adaptation cannot occur. (Research)
Evidence strength snapshot
The strongest repeated biochemical finding concerns vitamin K-dependent protein activation. Evidence for long-term Bone Health and Cardiovascular Health outcomes is mixed, while independent clinical data for MK-8 and MK-9 remain substantially less developed. (Research) (Review) (Research)
Safety, Interactions & Regulation
Adverse effects
Human randomized trials of Vitamin K2 have included exposure periods extending from weeks to several years, and adverse reactions have generally not shown a consistent major increase compared with controls in pooled postmenopausal bone research. However, trials designed primarily around bone-density outcomes cannot establish comprehensive safety in every population, especially for uncommon adverse events or interactions with medications. (Review)
The absence of a formally established tolerable upper intake level for vitamin K reflects the available safety evidence and regulatory evaluation; it should not be understood to mean that every dose, formulation, or combination is risk-free. (NIH ODS)
Interaction categories
Vitamin K antagonist anticoagulants: Vitamin K interacts with medicines such as warfarin and acenocoumarol because these drugs modify the vitamin K-dependent coagulation pathway. A controlled MK-7 study demonstrated that relatively small exposures could influence anticoagulant activity in participants using acenocoumarol. (Research) (NIH ODS)
Medications affecting fat absorption: NIH ODS identifies medications such as orlistat and bile acid sequestrants as relevant to vitamin K nutritional availability. These interactions concern absorption and vitamin status rather than proven therapeutic effects of MK-7 supplementation. (NIH ODS)
Antibiotics: Prolonged use of certain antibiotics can affect vitamin K status, partly through effects on intestinal microorganisms. This issue concerns vitamin K nutrition broadly and should not be interpreted as evidence that one K2 subtype has a specific corrective clinical effect. (NIH ODS)
Population cautions
People receiving vitamin K antagonist anticoagulation represent a population with a directly documented interaction concern. Individuals with conditions affecting fat absorption and those receiving complex medical treatments can also differ from otherwise healthy participants enrolled in standard nutritional trials. (Research) (NIH ODS)
Evidence from postmenopausal women or hemodialysis patients cannot automatically be generalized to pregnant individuals, children, or other clinical populations. Research in children has largely focused on biochemical outcomes rather than long-term clinical endpoints. (Research) (Research)
U.S. regulatory status
In the United States, vitamin K is an established dietary nutrient and Vitamin K2 forms are included in dietary supplement products. NIH ODS describes the different forms, nutritional reference intakes, dietary sources, and important medication interactions. Nutritional recognition does not by itself establish approval of MK-7 or MK-4 for treating a medical condition. (NIH ODS)
EU regulatory status
European Union rules include specified menaquinone-containing preparations within the framework governing authorized novel foods. These authorizations apply under defined conditions and specifications, so the regulatory status of a particular MK-7 ingredient depends on its identity, production process, and applicable food-category requirements. (EU Regulation)
Evidence Overview
Vitamin K2 has a substantial human research literature, but its strength differs considerably by subtype and outcome. Biochemical evidence is more consistent than evidence for improved clinical endpoints. Randomized trials repeatedly examine protein carboxylation, bone density, arterial stiffness, and vascular imaging, while dietary cohorts contribute observational evidence linking certain menaquinones to cardiovascular outcomes. Overall confidence is limited by inconsistent trial findings, differing populations and formulations, and the frequent use of surrogate measurements rather than fractures or cardiovascular events. (Review) (Review)
For Bone Health, MK-7 has been studied in randomized interventions extending to three years. One trial reported less age-related bone loss at selected skeletal sites, whereas another long-duration trial in women with osteopenia reported no meaningful improvement in bone density or microarchitecture. These differences cannot be resolved simply by comparing nominal dose, because populations, background nutrients, baseline skeletal characteristics, and measurement approaches also differed. (Research) (Research)
MK-4 represents a separate research context. Historical Japanese osteoporosis studies investigated milligram-range exposure and reported favorable fracture findings in some settings, whereas a more recent randomized study did not detect additional bone-density improvement when MK-4 was used alongside other therapies. These findings should not be combined uncritically with microgram-range MK-7 studies, given their differences in formulation, experimental dose, intervention context, and endpoints. (Research) (Research)
For Cardiovascular Health, randomized trials have produced different signals depending on which anatomical feature was measured. Some studies report improvements in arterial-stiffness measurements or coronary calcium-score progression, while others report no significant effect on aortic valve calcification or coronary calcification in dialysis populations. The combination of MK-7 with vitamin D3 creates an additional interpretive limitation because the separate contribution of each nutrient cannot be isolated. (Research) (Research) (Research)
Observational cohorts add an important but different kind of evidence. Higher dietary menaquinone intake has been associated with lower coronary disease incidence and less severe vascular calcification, including research encompassing MK-7, MK-8, and MK-9. However, fermented-food intake can be correlated with broader dietary patterns, and an observational association cannot establish that isolated supplementation would reproduce the same outcome. (Research) (Research)
Other areas, including Diabetes and Glycemic Control, Kidney Health, and Obesity and Weight Regulation, remain less convincing. Short-term metabolic improvements have not been consistently reproduced across studies of different populations, while hemodialysis trials and body-composition analyses have frequently produced neutral outcomes. (Research) (Research) (Research)
Future research would strengthen the evidence by independently replicating subtype-specific interventions, reporting baseline vitamin K status, standardizing imaging and biochemical endpoints, and following enough participants for clinically meaningful outcomes. Trials that distinguish MK-7 alone from MK-7 combined with vitamin D would also improve interpretation of currently mixed cardiovascular findings. These are research-design priorities arising from the limitations visible across the existing trials. (Review)
Evidence Confidence Classification
Limited / Mixed is the overall classification of Vitamin K2 human evidence for additional clinical benefits, because multiple randomized studies have investigated MK-4 and MK-7, but improvements in bone density, vascular calcification, and other clinical measures have not been consistently demonstrated across populations and trials. (Review) (Review)
The established nutritional role of vitamin K and the measurable activation of vitamin K-dependent proteins are supported more consistently than claims concerning fracture reduction, cardiovascular event reduction, or improved glucose control. (NIH ODS) (Research)
Within this classification, MK-7 has a larger body of controlled lower-dose intervention evidence than the other long-chain menaquinones included here, while MK-8 and MK-9 evidence remains primarily observational. MK-4 research has its own historical and pharmacological-dose characteristics and should be assessed separately rather than treated as equivalent evidence for MK-7. (Research) (Research)
Similar Ingredients & Comparators
Similar supplement-style ingredients and related nutrients
- Vitamin K1 (phylloquinone)
- MK-4 (menatetrenone)
- MK-7 (menaquinone-7)
- MK-8 (menaquinone-8)
- MK-9 (menaquinone-9)
- Vitamin D3 (cholecalciferol)
- Calcium
- Magnesium
- Vitamin D2 (ergocalciferol)
These entries are related by vitamin classification, nutritional physiology, or their appearance in the study contexts described above; inclusion does not imply equivalent clinical effects.
Medical / pharmaceutical comparator categories
- Antiresorptive osteoporosis medications
- Bone-forming osteoporosis medications
- Vitamin K antagonist anticoagulants
- Other anticoagulant medication classes
- Cardiovascular risk-management therapies
- Medical treatments for vitamin K deficiency
These categories are listed for research orientation, not as interchangeable alternatives.
Combination Context
Vitamin K2 + Vitamin D3:
This combination has been investigated in randomized studies of vascular calcification, including aortic valve and coronary artery calcium outcomes. Results have varied, and the combined designs limit attribution of observed changes to K2 alone. (Research) (Research)
Vitamin K2 + Calcium:
Calcium has been included as background supplementation in randomized research involving MK-7 and postmenopausal bone health. These designs examined whether MK-7 produced additional skeletal effects in participants receiving calcium, but long-term findings were not uniformly favorable. (Research)
Vitamin K2 + Calcium + Vitamin D3:
Combined nutritional exposure has been studied in postmenopausal women with osteopenia using biochemical tests, bone-density measurements, and bone-microarchitecture imaging. A three-year randomized follow-up did not establish an additional bone-density or microarchitecture benefit from MK-7 within this background regimen. (Research)
FAQ
What is Vitamin K2?
Vitamin K2 refers to a family of fat-soluble vitamins called menaquinones, including MK-4, MK-7, MK-8, and MK-9. These substances share the vitamin K chemical framework but have different molecular side chains and distributions in foods and tissues. Vitamin K participates in the activation of certain proteins involved in coagulation, bone biology, and mineral regulation. (NIH ODS)
What is the difference between MK-4 and MK-7?
MK-4 and MK-7 are different menaquinone molecules with distinct side-chain lengths and pharmacokinetic behavior. In controlled human comparisons, MK-7 produced a more persistent circulating exposure than MK-4 under the conditions studied. MK-4 has also been investigated in osteoporosis trials at 45 mg/day, whereas many MK-7 trials used doses measured in micrograms. These differences do not establish that one form produces better clinical outcomes in every setting. (Research) (Research)
What does human research study Vitamin K2 for?
Human Vitamin K2 studies principally examine Bone Health, Cardiovascular Health, and Nutrition and Deficiencies, particularly the activation of vitamin K-dependent proteins. Additional studies investigate Kidney Health, Diabetes and Glycemic Control, and Obesity and Weight Regulation. The research includes randomized clinical trials, observational dietary cohorts, and short-term absorption investigations. Evidence varies substantially by topic and experimental design. (Review) (Research) (Research)
What are the best-supported effects of Vitamin K2?
The clearest human experimental finding is its effect on selected vitamin K-dependent biochemical markers, particularly osteocalcin activation. Evidence for improvements in bone density or vascular measurements is less consistent. Changes in these measurements do not automatically establish reductions in fractures or cardiovascular events. (Research) (Review)
Does MK-7 improve bone density?
Some randomized MK-7 trials have reported less age-related bone-density loss at selected skeletal sites. However, another three-year randomized study found no significant improvement in bone density or microarchitecture compared with placebo. Differences in populations, outcome measurements, and background nutrient intake complicate comparisons. Consequently, the overall Bone Health evidence remains mixed. (Research) (Research)
Does Vitamin K2 reduce arterial calcification?
Randomized Vitamin K2 studies have reported different outcomes depending on the artery or valve examined and the population studied. Some coronary calcium-score investigations have reported favorable changes, while a two-year aortic valve calcification trial found no significant benefit. Studies combining K2 with vitamin D3 cannot determine the effect attributable exclusively to K2. Fewer cardiovascular events have not been established by these imaging findings. (Research) (Research) (Review)
What is known about MK-8 and MK-9?
MK-8 and MK-9 are longer-chain menaquinones associated with certain fermented foods. In human research, they have appeared primarily in dietary cohort analyses rather than isolated randomized supplementation studies. Higher dietary intake of certain menaquinones has been associated with lower coronary heart disease incidence, but the research does not establish a causal effect for isolated MK-8 or MK-9. Their individual clinical evidence is therefore more limited than the evidence for MK-7. (NIH ODS) (Research)
How quickly does MK-7 act?
Circulating MK-7 can be measured within hours after oral administration. Controlled pharmacokinetic research has reported peak concentrations around six hours after a single exposure. Biochemical studies have evaluated vitamin K-dependent protein responses over longer periods, while bone and cardiovascular trials generally require months or years to assess structural outcomes. A short time to peak concentration should not be confused with the onset of a proven clinical effect. (Research) (Research)
What affects Vitamin K2 absorption and variability?
Vitamin K2 is fat-soluble, and gastrointestinal fat-handling processes contribute to its absorption and transport. Different menaquinones have different circulating profiles, and food or manufacturing formulations can also affect how exposure is measured. Human research comparing MK-4 and MK-7 has demonstrated differences in blood persistence, while specific synthetic and fermented MK-7 preparations showed comparable availability in controlled studies. These findings do not guarantee identical absorption for all individuals or formulations. (NIH ODS) (Research) (Research)
Is tolerance to Vitamin K2 reported?
A defined tolerance syndrome has not been established in the long-term human Vitamin K2 trials considered here. These investigations primarily measured changes in bone density, vascular stiffness, calcification, or biochemical markers rather than systematically testing progressive loss of responsiveness. Therefore, the available findings are insufficient to describe a reliable tolerance timeline or an adaptation mechanism. (Research) (Research)
Why do Vitamin K2 studies disagree?
Vitamin K2 trials investigate different chemical forms, doses, participant groups, intervention durations, and outcome measurements. Some studies measure circulating biomarkers, others evaluate bone density, and others assess arterial or valve calcification. Studies of MK-7 combined with vitamin D3 introduce an additional difficulty because the individual contributions cannot be separated. Different results therefore do not necessarily represent a direct contradiction under identical experimental conditions. (Research) (Research)
What ingredients are studied in combination with Vitamin K2?
Vitamin D3 and calcium are the principal co-administered nutrients represented in the clinical trials reviewed here. Vitamin K2 plus D3 has been studied for vascular calcification, whereas trials involving calcium and D3 have focused primarily on postmenopausal bone outcomes. Results have been mixed, and combined supplementation does not establish that each ingredient independently contributed to an observed result. (Research) (Research)
What foods naturally contain Vitamin K2?
Vitamin K2 occurs in fermented and certain animal-derived foods, with the dominant subtype depending on the food. Natto is particularly associated with MK-7, while selected fermented cheeses contain longer-chain menaquinones, including MK-8 and MK-9. MK-4 is also associated with animal-derived foods and can be produced through metabolic conversion from vitamin K1. Food preparation and fermentation conditions influence the distribution of these compounds. (NIH ODS)
Does Vitamin K2 interact with anticoagulants?
Vitamin K2 can interfere with the activity of vitamin K antagonist anticoagulants because these drugs work through the vitamin K-dependent coagulation system. A controlled study found that relatively small doses of MK-7 could affect acenocoumarol anticoagulation. The observation concerns a clinically important drug interaction rather than a general adverse effect experienced by everyone consuming Vitamin K2. (Research) (NIH ODS)
How is Vitamin K2 regulated?
In the United States, Vitamin K2 is recognized within the broader dietary vitamin K category, and NIH ODS describes its nutritional forms and supplement context. This should be distinguished from authorization of specific medical treatment claims. In the European Union, particular menaquinone-containing novel-food ingredients are subject to authorization requirements and defined specifications. Regulatory rules concern ingredient identity and permitted use rather than proving that a clinical benefit has been established. (NIH ODS) (EU Regulation)
Resources
- Vitamin K — Health Professional Fact Sheet — NIH Office of Dietary Supplements — https://ods.od.nih.gov/factsheets/VitaminK-HealthProfessional/
- Three-year low-dose MK-7 supplementation and bone loss — Osteoporosis International, 2013 — https://pubmed.ncbi.nlm.nih.gov/23525894/
- Three-year MK-7 trial in postmenopausal osteopenia — Osteoporosis International, 2021 — https://pubmed.ncbi.nlm.nih.gov/33030563/
- MK-7 and arterial stiffness in postmenopausal women — Thrombosis and Haemostasis, 2015 — https://pubmed.ncbi.nlm.nih.gov/25694037/
- Vitamin K2 and D3 supplementation: DANCODE Trial — Circulation, 2026 — https://pubmed.ncbi.nlm.nih.gov/42661461/
- MK-4 versus MK-7 pharmacokinetics — Human comparative research, 2012 — https://pubmed.ncbi.nlm.nih.gov/23140417/
- Menaquinone intake and coronary heart disease — Prospect-EPIC cohort — https://pubmed.ncbi.nlm.nih.gov/19179058/
- MK-7 and vitamin K antagonist anticoagulation — Controlled human research — https://pubmed.ncbi.nlm.nih.gov/23530987/
- Vitamin K2 in postmenopausal osteoporosis — Systematic review and meta-analysis, 2022 — https://pubmed.ncbi.nlm.nih.gov/36033779/
- Vitamin K2 and aortic valve calcification — Randomized clinical trial, 2022 — https://pubmed.ncbi.nlm.nih.gov/35465686/
- MK-4 in osteoporosis research — Randomized study, 2023 — https://pubmed.ncbi.nlm.nih.gov/37338608/
- EU Union List of Authorized Novel Foods — European Commission — https://eur-lex.europa.eu/eli/reg_impl/2017/2470/eng